Community-Led Monitoring AP Database AP Data Dashboard
A Review of the Delamanid Patent Landscape: A Scoping Report
Publications
January 31, 2014

A Review of the Delamanid Patent Landscape: A Scoping Report

Delamanid was discovered via a screening programme carried out by Otsuka. The compound belongs to the nitroimidazole class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was already reported in 1993.

Download PDF

Delamanid was discovered via a screening programme carried out by Otsuka. The compound belongs to the nitroimidazole class of compounds and is a derivative of compound CGI-17341 whose anti-TB activity was already reported in 1993. Previously known as OPC-67683, delamanid is a mycolic-acid biosynthesis inhibitor found to be free of mutagenicity and to possess highly potent activity against tuberculosis (TB), including multidrug-resistant-tuberculosis (MDR-TB).

Organizations:

Unitaid

Share article:

Related Resources